Total Payments
$868.81
2024 Payments
$14.10
Companies
14
Transactions
45
Medicare Patients
5,569
Medicare Billing
$505,674
Payment Breakdown by Category
Food & Beverage$803.81 (92.5%)
Education$65.00 (7.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $803.81 | 44 | 92.5% |
| Education | $65.00 | 1 | 7.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $374.72 | 24 | $0 (2021) |
| Incyte Corporation | $108.13 | 2 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $92.72 | 1 | $0 (2018) |
| ABBVIE INC. | $80.42 | 6 | $0 (2022) |
| Celgene Corporation | $70.10 | 1 | $0 (2021) |
| Bayer Healthcare Pharmaceuticals Inc. | $25.49 | 2 | $0 (2024) |
| PFIZER INC. | $22.63 | 2 | $0 (2017) |
| Myovant Sciences Inc. | $15.80 | 1 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $14.63 | 1 | $0 (2017) |
| TOLMAR Pharmaceuticals, Inc. | $14.17 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14.10 | 1 | Bayer Healthcare Pharmaceuticals Inc. ($14.10) |
| 2023 | $12.93 | 1 | Sumitomo Pharma America, Inc. ($12.93) |
| 2022 | $55.43 | 4 | ABBVIE INC. ($42.99) |
| 2021 | $265.23 | 16 | Astellas Pharma US Inc ($155.26) |
| 2020 | $92.52 | 7 | Astellas Pharma US Inc ($79.46) |
| 2019 | $88.31 | 3 | Astellas Pharma US Inc ($88.31) |
| 2018 | $267.63 | 8 | Incyte Corporation ($108.13) |
| 2017 | $72.66 | 5 | Astellas Pharma US Inc ($35.40) |
All Payment Transactions
45 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $14.10 | General |
| Category: Oncology | ||||||
| 01/09/2023 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $12.93 | General |
| Category: Urology | ||||||
| 09/21/2022 | ABBVIE INC. | LUPRON DEPOT (Drug) | Food and Beverage | In-kind items and services | $17.18 | General |
| Category: ENDOCRINOLOGY | ||||||
| 07/25/2022 | ABBVIE INC. | LUPRON DEPOT (Drug) | Food and Beverage | In-kind items and services | $13.19 | General |
| Category: ENDOCRINOLOGY | ||||||
| 04/04/2022 | ABBVIE INC. | LUPRON DEPOT (Drug) | Food and Beverage | In-kind items and services | $12.62 | General |
| Category: ENDOCRINOLOGY | ||||||
| 01/10/2022 | UROVANT SCIENCES INC | GEMTESA (Drug) | Food and Beverage | Cash or cash equivalent | $12.44 | General |
| Category: Urology | ||||||
| 11/15/2021 | Astellas Pharma US Inc | XTANDI (Drug), MYRBETRIQ | Food and Beverage | In-kind items and services | $11.35 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2021 | Myovant Sciences Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $15.80 | General |
| Category: HORMONE THERAPY | ||||||
| 10/18/2021 | Astellas Pharma US Inc | XTANDI (Drug), MYRBETRIQ | Food and Beverage | In-kind items and services | $12.18 | General |
| Category: ONCOLOGY | ||||||
| 08/23/2021 | Astellas Pharma US Inc | XTANDI (Drug), MYRBETRIQ | Food and Beverage | In-kind items and services | $12.17 | General |
| Category: ONCOLOGY | ||||||
| 07/26/2021 | Astellas Pharma US Inc | XTANDI (Drug), MYRBETRIQ | Food and Beverage | In-kind items and services | $13.10 | General |
| Category: ONCOLOGY | ||||||
| 07/19/2021 | Bayer HealthCare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $11.39 | General |
| Category: Oncology | ||||||
| 07/08/2021 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $70.10 | General |
| 06/14/2021 | Astellas Pharma US Inc | XTANDI (Drug), MYRBETRIQ | Food and Beverage | In-kind items and services | $9.97 | General |
| Category: ONCOLOGY | ||||||
| 06/07/2021 | Astellas Pharma US Inc | MYRBETRIQ (Drug) | Food and Beverage | In-kind items and services | $12.63 | General |
| Category: UROLOGY | ||||||
| 05/10/2021 | Astellas Pharma US Inc | MYRBETRIQ (Drug) | Food and Beverage | In-kind items and services | $12.00 | General |
| Category: UROLOGY | ||||||
| 05/03/2021 | Astellas Pharma US Inc | XTANDI (Drug), MYRBETRIQ | Food and Beverage | In-kind items and services | $13.72 | General |
| Category: ONCOLOGY | ||||||
| 04/12/2021 | Allergan, Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $12.68 | General |
| Category: HYPERHYDROSIS | ||||||
| 04/05/2021 | Astellas Pharma US Inc | XTANDI (Drug), MYRBETRIQ | Food and Beverage | In-kind items and services | $14.60 | General |
| Category: ONCOLOGY | ||||||
| 03/08/2021 | Astellas Pharma US Inc | XTANDI (Drug), MYRBETRIQ | Food and Beverage | In-kind items and services | $14.91 | General |
| Category: ONCOLOGY | ||||||
| 02/08/2021 | Astellas Pharma US Inc | XTANDI (Drug), MYRBETRIQ | Food and Beverage | In-kind items and services | $15.18 | General |
| Category: ONCOLOGY | ||||||
| 01/11/2021 | Astellas Pharma US Inc | XTANDI (Drug), MYRBETRIQ | Food and Beverage | In-kind items and services | $13.45 | General |
| Category: ONCOLOGY | ||||||
| 12/21/2020 | Astellas Pharma US Inc | XTANDI (Drug), MYRBETRIQ | Food and Beverage | In-kind items and services | $14.21 | General |
| Category: ONCOLOGY | ||||||
| 11/16/2020 | Astellas Pharma US Inc | XTANDI (Drug), MYRBETRIQ | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: ONCOLOGY | ||||||
| 10/05/2020 | Astellas Pharma US Inc | XTANDI (Drug), MYRBETRIQ | Food and Beverage | In-kind items and services | $12.68 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 971 | 1,608 | $259,840 | $88,778 |
| 2022 | 9 | 1,129 | 1,895 | $283,011 | $108,205 |
| 2021 | 13 | 1,594 | 2,594 | $367,961 | $135,975 |
| 2020 | 17 | 1,875 | 3,026 | $478,204 | $172,715 |
Total Patients
5,569
Total Services
9,123
Medicare Billing
$505,674
Procedure Codes
48
All Medicare Procedures & Services
48 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 386 | 676 | $60,840 | $37,106 | 61.0% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 27 | 222 | $120,020 | $29,082 | 24.2% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Office | 2023 | 66 | 78 | $46,410 | $11,921 | 25.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 41 | 41 | $13,325 | $6,340 | 47.6% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 27 | 74 | $3,700 | $1,440 | 38.9% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2023 | 168 | 202 | $9,090 | $1,304 | 14.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 12 | 12 | $1,800 | $867.05 | 48.2% |
| 81003 | Automated urinalysis test | Office | 2023 | 232 | 290 | $2,900 | $638.00 | 22.0% |
| 51741 | Electronic assessment of bladder emptying | Office | 2023 | 12 | 13 | $1,755 | $79.08 | 4.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 439 | 830 | $74,595 | $48,695 | 65.3% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2022 | 30 | 216 | $116,776 | $30,071 | 25.8% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Office | 2022 | 73 | 82 | $48,790 | $13,788 | 28.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 61 | 61 | $19,775 | $9,668 | 48.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 24 | 24 | $3,600 | $1,888 | 52.5% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2022 | 187 | 240 | $10,800 | $1,633 | 15.1% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 30 | 72 | $3,600 | $1,602 | 44.5% |
| 81003 | Automated urinalysis test | Office | 2022 | 274 | 359 | $3,590 | $796.20 | 22.2% |
| 51741 | Electronic assessment of bladder emptying | Office | 2022 | 11 | 11 | $1,485 | $63.29 | 4.3% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2021 | 45 | 346 | $187,058 | $50,433 | 27.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 496 | 959 | $72,000 | $47,583 | 66.1% |
| 52000 | Diagnostic examination of the bladder and bladder canal (urethra) using an endoscope | Office | 2021 | 79 | 87 | $51,765 | $14,329 | 27.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 76 | 76 | $20,900 | $11,592 | 55.5% |
| 96402 | Hormonal anti-neoplastic chemotherapy administration beneath the skin or into muscle | Office | 2021 | 45 | 124 | $6,200 | $2,496 | 40.3% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 53 | 65 | $3,585 | $2,359 | 65.8% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2021 | 219 | 292 | $13,140 | $1,801 | 13.7% |
About Dr. Naeem Pervaiz, MD
Dr. Naeem Pervaiz, MD is a Urology healthcare provider based in Princeton, West Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1952367666.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Naeem Pervaiz, MD has received a total of $868.81 in payments from pharmaceutical and medical device companies, with $14.10 received in 2024. These payments were reported across 45 transactions from 14 companies. The most common payment nature is "Food and Beverage" ($803.81).
As a Medicare-enrolled provider, Pervaiz has provided services to 5,569 Medicare beneficiaries, totaling 9,123 services with total Medicare billing of $505,674. Data is available for 4 years (2020–2023), covering 48 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Location Princeton, WV
- Active Since 04/21/2006
- Last Updated 07/01/2013
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1952367666
Products in Payments
- XTANDI (Drug) $237.41
- JAKAFI (Drug) $108.13
- ELIQUIS (Drug) $92.72
- LUPRON DEPOT (Drug) $56.05
- MYRBETRIQ (Drug) $36.91
- Myrbetriq (Drug) $35.40
- Nubeqa (Drug) $25.49
- GEMTESA (Drug) $25.37
- VIAGRA (Drug) $22.63
- ORGOVYX (Drug) $15.80
- BRIDION (Drug) $14.63
- ELIGARD (Drug) $14.17
- Lupron (Drug) $12.91
- BOTOX (Biological) $12.68
- Erleada (Drug) $11.95
- Androgel (Drug) $11.46
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in Princeton
Dr. Alexander Vukasin, M.d, M.D
Urology — Payments: $6,260
Urology $6,260
Dr. Alexei Wedmid, Md, MD
Urology — Payments: $3,313
Urology $3,313
Dr. Barry Rossman, M.d, M.D
Urology — Payments: $3,134
Urology $3,134
Dr. Sidney Goldfarb, Md, MD
Urology — Payments: $2,117
Urology $2,117
Karen Latzko, D.o, D.O
Urology — Payments: $2,024
Urology $2,024
Marc Schwarzman, M.d, M.D
Urology — Payments: $570.85
Urology $570.85